BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)

Stopped early · Phase 4

Conditions studied: HIV Infections

In brief

This study will look to see if increasing the standard dose of Kaletra is tolerated and if it will lower viral loads to undetectable levels. This study will also look at the pharmacokinetic data (amount of Kaletra in blood at different times).

Key facts

Study ID

NCT00414284

Run by

Community Research Initiative of New England

Starts

2006-06-01

Expected to finish

2007-04-01

Last updated by the study team

2010-12-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• CD4 Count >50
• Viral load 200-75,000 on two most recent measures
• More than 16 weeks on standard dose Kaletra (LPV/r)
• May be initial PI regimen or prior PI usage
• Up to 50-fold resistance to LPV/r

You may not qualify if…

• Age < 18 years old

Where it is running

• Community Research Initiative of New England - Boston — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.